Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was approximately $14.5 million, a decline from $17.5 million in the same period last year, reflecting various operational challenges [10] - The gross profit margin decreased, particularly in the healthcare segment due to lower 340B contract revenue and increased operational costs in the e-commerce segment [12][14] - The company ended the quarter with approximately $17.7 million in cash [12] Business Line Data and Key Metrics Changes - In the healthcare segment, there was a decline in prescription volume and changes in pharmacy service agreements, impacting revenue [10][14] - E-commerce operations saw an increase in recurring airtime revenue, which grew by 51%, but this was offset by a decline in hardware sales [11][16] - The healthcare operations are shifting focus towards long-term contracts and new service offerings to improve margins [14] Market Data and Key Metrics Changes - The current tariff situation has significantly impacted the launch of Florida Sunshine products in China, leading to a pause in those plans [5][19] - The company is exploring other markets for Florida Sunshine and has seen steady progress in launching OpCo products in China [6][19] Company Strategy and Development Direction - The company is evaluating strategic alternatives, including potential sales or mergers of certain operations and exploring new partnerships [9] - There is a commitment to improving operational efficiency and cost structure in the healthcare segment, with a focus on 340B pharmacy service agreements [14] - The company aims to achieve a cash neutral position from operations by 2026, although current conditions may delay this goal [8] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges due to tariffs and the need to explore alternative markets and products [6][19] - There is optimism regarding the potential for growth in the e-commerce segment, particularly in high-margin recurring revenue streams [16] - The management is committed to transparency and addressing industry challenges to maximize shareholder value [21] Other Important Information - The company received a substantial performance bonus from a payer, recognizing its execution and focus on quality [14] - The company is actively working on cost-saving initiatives and renegotiating vendor contracts to improve its financial position [13] Q&A Session Summary Question: What is the status of the share buyback? - The company has not repurchased any shares due to legal blackout periods and the need to evaluate cash uses for long-term shareholder value [22][23] Question: Can you comment on Jervis Hall's resignation as director? - The resignation was not due to any disagreement with the company, and while a replacement may be considered, it is not required at this time [24] Question: What is the plan to address the NASDAQ letter and minimum bid requirement? - The company has a six-month period to address the share price and intends to improve financial results and explore strategic alternatives [25][26] Question: What is the status of ongoing litigation? - The company cannot comment on ongoing litigation matters [26]

Core Insights - NextPlat Corp reported Q1 2025 revenue of approximately $14.5 million, a decrease from $17.5 million in Q1 2024, primarily due to challenges in Healthcare Operations and changes in pharmacy service agreements [5][2] - The company is focusing on cost reduction and efficiency improvements, with operating expenses decreasing by 26.2% to approximately $4.9 million compared to $6.7 million in the prior year [5][2] - The net loss attributable to common shareholders decreased by 9% to approximately $1.3 million, or ($0.05) per diluted share, compared to a net loss of approximately $1.5 million, or ($0.08) per diluted share in Q1 2024 [5][2] Financial Highlights - Consolidated revenue for Q1 2025 was approximately $14.5 million, down from $17.5 million in Q1 2024 [5] - Gross profit margin declined to 23.8% from 27.8% year-over-year, with the Healthcare segment's gross profit margin decreasing to 23.8% from 27.7% [5] - Operating expenses decreased by 26.2% to approximately $4.9 million, attributed to the elimination of non-recurring expenses [5] Business Developments - The company signed several new 340B pharmacy service agreements expected to contribute to revenue growth and improved margins [5] - NextPlat's e-Commerce operations saw a 51% increase in recurring airtime revenue, driven by new connectivity contracts and partnerships [5][6] - The company is exploring strategic alternatives to diversify its Healthcare Operations, including new services and joint ventures [5] Cash Position - NextPlat ended the quarter with approximately $17.7 million in cash [5] - The company continues to evaluate its financial position and operational strategies to enhance growth and profitability [2][5]

[PART I. FINANCIAL INFORMATION](index=5&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Item 1. Condensed Consolidated Financial Statements (Unaudited)](index=5&type=section&id=ITEM%201.%20Condensed%20Consolidated%20Financial%20Statements%20(Unaudited)) Q1 2025 unaudited financials report total assets of $35.2 million, a net loss of $1.34 million, and $2.1 million net cash used in operations [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to $35.2 million by March 31, 2025, driven by reduced cash, with total equity declining to $25.5 million | Balance Sheet Highlights (In thousands) | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Total Current Assets** | $30,475 | $31,480 | | Cash | $17,737 | $19,960 | | **Total Assets** | **$35,204** | **$36,478** | | **Total Current Liabilities** | $8,424 | $8,210 | | **Total Liabilities** | **$9,753** | **$9,680** | | **Total Equity** | **$25,451** | **$26,798** | [Condensed Consolidated Statements of Comprehensive Loss](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Loss) Q1 2025 net revenue decreased 17% to $14.5 million, but reduced operating expenses led to a smaller net loss of $1.34 million | Income Statement (In thousands) | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Revenue, net | $14,525 | $17,493 | | Gross profit | $3,463 | $4,863 | | Total operating expenses | $4,948 | $6,705 | | Net loss | $(1,343) | $(1,701) | | Basic and diluted loss per share | $(0.05) | $(0.08) | - The decrease in operating expenses was largely due to a significant reduction in intangible asset amortization, which fell from **$698,000** in Q1 2024 to just **$26,000** in Q1 2025[17](index=17&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities improved to $2.1 million in Q1 2025, with the cash balance ending at $17.7 million | Cash Flow Summary (In thousands) | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(2,059) | $(2,685) | | Net cash used in investing activities | $(22) | $(63) | | Net cash used in financing activities | $(134) | $(1) | | **Net decrease in cash** | **$(2,223)** | **$(2,781)** | | **Cash end of period** | **$17,737** | **$23,526** | [Notes to Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail company structure, accounting policies, and financial components, highlighting the Outfitter Satellite acquisition, segment performance, and ongoing litigation - The company operates through two main business segments: **e-Commerce Operations** (including satellite communication services) and **Healthcare Operations** (pharmacy and related services)[25](index=25&type=chunk)[26](index=26&type=chunk)[29](index=29&type=chunk) - On April 1, 2024, NextPlat acquired **100%** of Outfitter Satellite, Inc. to expand its Satellite Industry services in the U.S.[28](index=28&type=chunk) | Revenue by Category (In thousands) | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | e-Commerce revenue | $3,006 | $2,865 | | Pharmacy prescription revenue | $10,090 | $11,324 | | Pharmacy 340B contract revenue | $1,429 | $3,304 | | **Total Revenues, net** | **$14,525** | **$17,493** | - The company is involved in several legal proceedings, including a class action lawsuit concerning the Progressive Care merger and an EEOC claim from a former employee, which it is vigorously defending[85](index=85&type=chunk)[86](index=86&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=30&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes the 17% revenue decrease to Healthcare segment declines, operating expenses fell by $1.8 million, and current cash is sufficient for 12 months [Results of Operations](index=32&type=section&id=Results%20of%20Operations) Q1 2025 total revenue decreased 17% to $14.5 million due to Healthcare segment declines, while operating expenses fell 26%, reducing net loss | Financial Summary (In thousands) | Q1 2025 | Q1 2024 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Revenue, net | $14,525 | $17,493 | $(2,968) | (17)% | | Gross profit | $3,463 | $4,863 | $(1,400) | (29)% | | Operating expenses | $4,948 | $6,705 | $(1,757) | (26)% | | Net loss | $(1,343) | $(1,701) | $358 | (21)% | - The decrease in revenue was primarily due to a decline in the Healthcare segment, with pharmacy prescription revenue falling by **$1.2 million** and 340B contract revenue decreasing by **$1.9 million**[123](index=123&type=chunk)[124](index=124&type=chunk) - The significant drop in operating expenses was mainly due to a **$0.7 million** decrease in intangible asset amortization and a **$0.4 million** reduction in professional fees[130](index=130&type=chunk)[132](index=132&type=chunk) [Liquidity and Capital Resources](index=36&type=section&id=Liquidity%20and%20Capital%20Resources) As of March 31, 2025, the company held $17.7 million in cash and $22.1 million in working capital, deemed sufficient for the next 12 months, with ongoing cost-reduction efforts - The company's cash balance was approximately **$17.7 million** as of March 31, 2025[137](index=137&type=chunk) - Management asserts that existing cash resources are sufficient to support planned operations for at least the next **12 months**[138](index=138&type=chunk) - Cost reduction measures are being implemented to improve efficiency and preserve liquidity, and management is exploring strategic alternatives, including a possible sale or merger of a portion of the business[137](index=137&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=38&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, NextPlat Corp is exempt from providing quantitative and qualitative disclosures about market risk - The company is exempt from this disclosure requirement due to its status as a smaller reporting company[144](index=144&type=chunk) [Item 4. Controls and Procedures](index=38&type=section&id=Item%204.%20Controls%20and%20Procedures) As of March 31, 2025, disclosure controls and procedures were deemed ineffective due to a material weakness in inventory valuation, with remediation efforts ongoing for Q2 2025 completion - The CEO and CFO concluded that disclosure controls and procedures were **not effective** as of March 31, 2025[145](index=145&type=chunk) - A material weakness related to controls over the valuation of inventories was identified in fiscal 2024 and is still being remediated[146](index=146&type=chunk) - Remediation efforts are underway, including implementing new policies and enhancing management review of inventory valuation, with completion anticipated by the end of Q2 2025[146](index=146&type=chunk) [PART II. OTHER INFORMATION](index=39&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=39&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in several legal proceedings, including an EEOC claim, a class action suit related to a merger, and an employment contract dispute, all being vigorously defended - A former employee of subsidiary Pharmco LLC filed a lawsuit asserting claims under **EEOC regulations** on March 17, 2025[150](index=150&type=chunk) - A class action suit was filed by Alan Jay Weisberg, former CEO of Progressive Care Inc., alleging breach of fiduciary duty and insufficient consideration in the **October 1, 2024 merger**[151](index=151&type=chunk) - The company is also in an arbitration dispute with a former employee over an alleged breach of an employment contract, where the company has filed a counterclaim[153](index=153&type=chunk) [Item 1A. Risk Factors](index=40&type=section&id=Item%201A.%20Risk%20Factors) The U.S./China tariff environment poses a significant risk, leading the company to pause certain e-Commerce initiatives like the 'Florida Sunshine' brand launch in China due to reduced competitiveness - The ongoing **U.S./China tariff environment** poses a significant risk to the company's business, financial condition, and profitability[157](index=157&type=chunk) - The company plans to pause the introduction of its **Florida Sunshine brand** of vitamins in China due to the adverse impact of tariffs on competitiveness[158](index=158&type=chunk) - Sales of products manufactured by OPKO Health Europe in China will continue as they are not produced in the U.S. and thus not subject to the additional tariffs[159](index=159&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=40&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales of equity securities or use of proceeds were reported during the period - None reported for the quarter[161](index=161&type=chunk) [Item 3. Defaults Upon Senior Securities](index=40&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) No defaults upon senior securities were reported during the period - None reported for the quarter[162](index=162&type=chunk) [Item 4. Mine Safety Disclosures](index=40&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company's operations - Not applicable[163](index=163&type=chunk) [Item 5. Other Information](index=40&type=section&id=Item%205.%20Other%20Information) No director or officer adopted or terminated any Rule 10b5-1 trading arrangement during Q1 2025 - No director or officer adopted or terminated a Rule 10b5-1 trading arrangement during the quarter[164](index=164&type=chunk) [Item 6. Exhibits](index=41&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with Form 10-Q, including Sarbanes-Oxley Act certifications and Inline XBRL data files - Lists required certifications under Sections 302 and 906 of the Sarbanes-Oxley Act and XBRL financial data files as exhibits[165](index=165&type=chunk)

Core Viewpoint - NextPlat Corp is set to release its financial results for the quarter ended March 31, 2025, on May 15, 2025, before market open, and will host a conference call to discuss these results and other developments [1][2]. Group 1: Financial Results Announcement - NextPlat Corp will announce its financial results for Q1 2025 on May 15, 2025, before the market opens [1]. - The conference call will take place at 8:30 a.m. Eastern time on the same day [2]. Group 2: Conference Call Details - The call will be hosted by Executive Chairman and CEO Charles M. Fernandez, CFO Cecile Munnik, and President and CEO of Global Operations David Phipps [2]. - Investors can submit questions for the Q&A portion of the call before May 12, 2025 [2]. - Access details for the call include a toll-free dial-in number (1-800-836-8184) and an international dial-in number (1-646-357-8785) [2]. Group 3: Replay Information - The conference call will be available for live broadcast and replay on the company's website [3]. - A replay will be accessible after 12:00 p.m. Eastern time on May 15, 2025, through March 22, 2025 [3]. - The toll-free replay number is 1-888-660-6345, and the international replay number is 1-646-517-4150 [3]. Group 4: Company Overview - NextPlat is a global e-commerce platform focusing on high-growth sectors such as technology and healthcare [4]. - The company aims to assist businesses in enhancing their online sales through various strategies, including acquisitions and collaborations [4]. - NextPlat operates an e-commerce communications division and provides healthcare data management services in the U.S. through its subsidiary, Progressive Care LLC [4].

Core Viewpoint - NextPlat Corp has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, as its closing bid price has been below $1.00 for 30 consecutive business days [1][2]. Compliance Period - The company has been granted a 180-calendar day compliance period until October 27, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days [2]. - If compliance is not achieved by the deadline, NextPlat may qualify for a second 180-calendar day compliance period, provided it meets other listing requirements [3]. Company Response - The Executive Chairman and CEO of NextPlat stated that the company is actively addressing challenges in drug pricing and tariff escalations, while also working to reduce operating expenses and improve business efficiency [4]. - The company plans to monitor its stock price and explore options to regain compliance during the compliance period [4]. Company Overview - NextPlat is a global e-commerce platform focused on high-growth sectors, including technology and healthcare, and aims to assist businesses in optimizing their online sales [6]. - The company operates an e-commerce communications division and provides pharmacy and healthcare data management services through its subsidiary, Progressive Care LLC [6].

Core Insights - NextPlat Corp's subsidiary, Global Telesat Communications Ltd, has secured a one-year extension for a wireless connectivity services contract with an African military customer, expected to enhance growth in connectivity services revenue through 2025 [1][4]. Contract Details - The original contract for Iridium Push-To-Talk (PTT) device hardware and related airtime services was awarded in Q1 2024, marking the largest contract of its kind in the company's history [2]. - The extension includes options for additional hardware purchases and annual airtime services, with all sales exempt from recent US tariffs [2]. Product Significance - Iridium Extreme® PTT devices are increasingly favored by government, military, and enterprise customers for their secure and reliable global communication capabilities, essential for multi-national operations and emergency responses [3]. - The devices are designed for challenging environments, offering global coverage and advanced push-to-talk features [3]. Management Commentary - The renewal of the contract reflects the growing international interest in Iridium PTT devices from various government and enterprise organizations, highlighting the trust placed in the company to meet connectivity needs [4].

Core Viewpoint - The company is pausing the introduction of US-produced products, including its Florida Sunshine brand of vitamins and supplements, in China due to the impact of increased tariffs, while continuing to sell OPKO-branded products that are not subject to these tariffs [1][2][3]. Group 1: Impact of Tariffs - The company expects a material impact on anticipated sales of US products into China due to the escalation of tariffs on US goods [1]. - The pause in initiatives is specifically related to the e-Commerce development program aimed at helping US businesses access the Chinese market through platforms like Alibaba's Tmall [2]. Group 2: Product Strategy - The company will continue selling OPKO Health Europe products in China, which include nutraceuticals and supplements, as these products are not produced in the US and thus are not affected by the tariffs [3]. - The company is exploring opportunities to sell Florida Sunshine products in other markets outside of China [2]. Group 3: Company Overview - NextPlat Corp is a global e-commerce platform that aims to capitalize on high-growth sectors, including technology and healthcare, through various business strategies such as acquisitions and joint ventures [4]. - The company operates an e-commerce communications division and provides pharmacy and healthcare data management services in the US through its subsidiary, Progressive Care LLC [4].

Core Insights - NextPlat Corp's subsidiary, Global Telesat Communications Ltd, has secured a connectivity services contract from a central UK Government department, marking the first contract of this nature for GTC [1][2] - The contract involves providing Iridium Push-To-Talk (PTT) devices and recurring airtime services, aimed at enhancing communication for government staff involved in policy development and coordination [2][4] - Initial product shipments are expected in the second quarter, with the products not impacted by recent US tariffs [2] Company Overview - NextPlat is a global e-commerce platform focused on high-growth sectors such as technology and healthcare, aiming to assist businesses in optimizing their online sales [6] - The company operates an e-commerce communications division that offers voice, data, tracking, and IoT products and services globally, along with pharmacy and healthcare data management services in the US through its subsidiary, Progressive Care LLC [6]

[NextPlat Fiscal Year 2024 Performance Review](index=1&type=section&id=NextPlat%20Fiscal%20Year%202024%20Performance%20Review) [Full Year 2024 Financial Highlights](index=1&type=section&id=Full%20Year%202024%20Financial%20Highlights) NextPlat's 2024 revenue grew 73% to $65.5 million, but net loss widened to $14.0 million due to rising costs FY 2024 vs. FY 2023 Key Financial Metrics | Metric | FY 2024 | FY 2023 | Change | | :--- | :--- | :--- | :--- | | **Consolidated Revenue** | $65.5M | $37.8M | +73% | | **Gross Profit Margin** | 24.8% | N/A (Implied 30.0%) | Decline | | **Operating Expenses** | $40.0M | $34.6M | +15.6% | | **Net Loss (to Common Shareholders)** | ($14.0M) | ($3.8M) | Widened | | **Diluted Loss Per Share** | ($0.68) | ($0.22) | Widened | - The **73% revenue growth** was primarily attributed to an increase of approximately **$24.9 million** from a full year of Healthcare Operations in 2024 versus only six months in 2023[6](index=6&type=chunk) - Gross margins for both e-Commerce Operations (**24.9%**) and Healthcare Operations (**24.8%**) declined year-over-year due to rising inventory costs, pricing pressures, and medication price increases outpacing reimbursement rates[6](index=6&type=chunk) - The company ended 2024 with **$20.0 million in cash**, reflecting a net cash burn of **$6.3 million**, which included **$3.4 million** in non-recurring merger-related expenses and **$1.0 million** for the Outfitter Satellite acquisition[6](index=6&type=chunk) [Organizational Highlights and Recent Business Developments](index=1&type=section&id=Organizational%20Highlights%20and%20Recent%20Business%20Developments) NextPlat completed strategic mergers and acquisitions, expanded healthcare and e-commerce operations, and advanced its China market entry - Completed a merger with Progressive Care, making it a wholly owned subsidiary, and acquired Outfitter Satellite Inc. to expand satellite product sales in North America[6](index=6&type=chunk) - Healthcare Operations filled approximately **514,000 prescriptions** and is expanding its higher-margin pharmacy service contracts with 340B covered entities[6](index=6&type=chunk) - The e-Commerce business achieved a **115% increase** in high-margin recurring airtime contract revenue, driven by new hardware solutions like Starlink and expanded provider relationships[6](index=6&type=chunk) - Expanded its e-commerce program in China by launching OPKO-branded products on Alibaba's Tmall Global and securing access to over **340 million** additional consumers through an agreement with J.D.com[7](index=7&type=chunk) - Progressed the development of its 'Florida Sunshine' line of vitamins and supplements, with plans to launch on Amazon in the US and EU, and market in China starting late Q2 2025[7](index=7&type=chunk) [Management Commentary](index=1&type=section&id=Management%20Commentary) Management expressed satisfaction with strategic growth initiatives, highlighting e-commerce expansion, healthcare efforts, and strong demand for satellite connectivity - CEO Charles M. Fernandez stated that 2024 results reflect progress in strategic initiatives, including expanding e-Commerce in the US and China and supporting a growing number of 340B entities in healthcare[3](index=3&type=chunk) - President David Phipps commented on the strong demand for satellite-based connectivity and the company's positioning to capitalize on growing Chinese consumer demand for health and wellness products[7](index=7&type=chunk) [Conference Call Information](index=2&type=section&id=Conference%20Call%20Information) NextPlat will host a conference call on March 24, 2025, at 8:30 a.m. ET to discuss fiscal year 2024 results Conference Call Details | Item | Details | | :--- | :--- | | **Date** | Monday, March 24, 2025 | | **Time** | 8:30 a.m. Eastern time | | **Toll-free dial-in** | 1-800-836-8184 | | **International dial-in** | 1-646-357-8785 | | **Webcast Link** | https://app.webinar.net/1B37G1wAapL | Replay Information (Available through March 31, 2025) | Item | Details | | :--- | :--- | | **Toll-free replay** | 1-888-660-6345 | | **International replay** | 1-646-517-4150 | | **Replay entry code** | 70962 | [Consolidated Financial Statements](index=4&type=section&id=Consolidated%20Financial%20Statements) [Consolidated Statements of Comprehensive Loss](index=4&type=section&id=Consolidated%20Statements%20of%20Comprehensive%20Loss) NextPlat's 2024 net revenue grew 73% to $65.5 million, but total operating expenses led to a $14.0 million net loss Consolidated Statement of Comprehensive Loss Highlights (in thousands) | Line Item | 2024 | 2023 | | :--- | :--- | :--- | | **Revenue, net** | $65,483 | $37,756 | | **Gross profit** | $16,229 | $11,311 | | **Total operating expenses** | $39,853 | $34,539 | | **Net loss** | ($23,125) | ($12,407) | | **Net loss attributable to NextPlat Corp** | ($14,025) | ($3,778) | | **Basic and diluted loss per share** | ($0.68) | ($0.22) | [Consolidated Balance Sheets](index=5&type=section&id=Consolidated%20Balance%20Sheets) NextPlat's total assets decreased to $36.5 million by year-end 2024, with cash at $20.0 million and total equity at $26.7 million Consolidated Balance Sheet Highlights (in thousands) | Line Item | Dec 31, 2024 | Dec 31, 2023 | | :--- | :--- | :--- | | **Cash** | $19,960 | $26,307 | | **Total Current Assets** | $31,480 | $43,638 | | **Total Assets** | $36,478 | $64,469 | | **Total Current Liabilities** | $8,210 | $14,237 | | **Total Liabilities** | $9,680 | $16,382 | | **Total Equity** | $26,798 | $48,087 |

NextPlat Corp (NASDAQ:NXPL) Q4 2024 Earnings Conference Call March 24, 2025 8:30 AM ET Company Participants Charles Fernandez - CEO and Executive Chairman of the Board David Phipps - President and CEO of Global Operations Cecile Munnik - CFO Conference Call Participants Operator Welcome to the NextPlat Corp 2024 Earnings Conference Call. Certain statements made during this conference call constitute forward-looking statements. These statements include the capabilities and success of the Company's business a ...